Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

BACKGROUND: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicity of this new vaccine in West African volunteers. METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brookes, R, Hill, A, Owiafe, P, Ibanga, H, Jeffries, D, Donkor, SA, Fletcher, H, Hammond, A, Lienhardt, C, Adegbola, R, McShane, H
Formato:	Journal article
Lenguaje:	English
Publicado:	Public Library of Science 2008

Ejemplares similares

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Roger H Brookes, et al.
Publicado: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
por: Roger H. Brookes, et al.
Publicado: (2011-01-01)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
por: Ibanga, H, et al.
Publicado: (2006)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
por: Owiafe, P, et al.
Publicado: (2012)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
por: Ota, M, et al.
Publicado: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
por: Ota, M, et al.
Publicado: (2011)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, A, et al.
Publicado: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
por: Pathan, A, et al.
Publicado: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
por: Meyer, J, et al.
Publicado: (2013)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
por: Mcshane, H, et al.
Publicado: (2005)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
por: Whelan, K, et al.
Publicado: (2009)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
por: Meyer, J, et al.
Publicado: (2013)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
por: Rowland, R, et al.
Publicado: (2012)

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.
por: Ota, M, et al.
Publicado: (2007)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
por: Harris, S, et al.
Publicado: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Publicado: (2011-01-01)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
por: White, A, et al.
Publicado: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, A, et al.
Publicado: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
por: Hawkridge, T, et al.
Publicado: (2008)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
por: Betts, G, et al.
Publicado: (2012)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
por: Kathryn T. Whelan, et al.
Publicado: (2011-01-01)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
por: Sander, C, et al.
Publicado: (2009)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
por: Rowland, R, et al.
Publicado: (2013)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
por: Tameris, M, et al.
Publicado: (2014)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
por: Thomas, Z, et al.
Publicado: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
por: Minhinnick, A, et al.
Publicado: (2016)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
por: Odutola, A, et al.
Publicado: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
por: Odutola, A, et al.
Publicado: (2012)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
por: Fletcher, H, et al.
Publicado: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, A, et al.
Publicado: (2017)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
por: Griffiths, K, et al.
Publicado: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
por: Griffiths, K, et al.
Publicado: (2011)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
por: Gareth Betts, et al.
Publicado: (2012-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
por: Harris, S, et al.
Publicado: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
por: Riste, M, et al.
Publicado: (2021)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
por: Tameris, M, et al.
Publicado: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
por: Satti, I, et al.
Publicado: (2014)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
por: Wilkie, M, et al.
Publicado: (2019)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
por: Dieye, T, et al.
Publicado: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
por: Mcshane, H
Publicado: (2008)